Health Insurance Review and Assessment Service Reports Findings in Hemodialysis (Effect of spironolactone on survival in patients undergoing maintenance hemodialysis): Dialysis – Hemodialysis

2024 APR 17 (NewsRx) -- By a News Reporter-Staff News Editor at South Korea Daily Report -- New research on Dialysis - Hemodialysis is the subject of a report. According to news originating from Wonju, South Korea, by NewsRx correspondents, research stated, “Previous studies have reported inconsistent results regarding the advantages or disadvantages of spironolactone use in patients undergoing hemodialysis (HD). This study aimed to evaluate survival according to the use of spironolactone in a large sample of patients undergoing maintenance HD.”

Financial support for this research came from The Basic Science Research Program through the NRF of Korea, funded by the Ministry of Education.

Our news journalists obtained a quote from the research from Health Insurance Review and Assessment Service, “This retrospective study used laboratory and clinical data from the national HD Quality Assessment Program and claims data. The participants of the quality assessment program were patients who had been undergoing maintenance HD for 3 months, patients undergoing HD at least twice a week. Patients with no spironolactone prescription during the assessment periods were designated as the control group. Patients with one or more prescriptions of spironolactone during the assessment periods were assigned to the SPR group. The number of patients in the control and SPR groups were 54,588 and 315, respectively. The 5-year survival rates were 69.1% and 59.1% in the control and SPR groups, respectively (P < 0.001). Cox regression analyses showed that the hazard ratio in the SPR group was 1.34 (P < 0.001) in univariate analysis and 1.13 (P = 0.249) in multivariable analysis. Univariate Cox-regression analysis showed a better patient survival rate in the control group than in the SPR group; however, multivariable analyses showed similar patient survival rates between the two groups.”

According to the news editors, the research concluded: “This study showed no difference in survival between patients undergoing HD with and without spironolactone use.”

For more information on this research see: Effect of spironolactone on survival in patients undergoing maintenance hemodialysis. PLOS ONE, 2024;19(3). PLOS ONE can be contacted at: Public Library Science, 1160 Battery Street, Ste 100, San Francisco, CA 94111, USA. (Public Library of Science - www.plos.org; PLOS ONE - www.plosone.org)

The news correspondents report that additional information may be obtained from Bo Yeon Kim, Healthcare Review and Assessment Committee, Health Insurance Review and Assessment Service, Wonju, South Korea. Additional authors for this research include Seok Hui Kang, Eun Jung Son, Gui Ok Kim and Jun Young Do.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1371/journal.pone.0301458. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher’s contact information for the journal PLOS ONE is: Public Library Science, 1160 Battery Street, Ste 100, San Francisco, CA 94111, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)